Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO

Inclusion criteria

• Diagnosis of non-segmental vitiligo affecting at least 10% of BSA since at least 3 months.
• Patient requiring a treatment by UVB
• For both female of childbearing potential and male patients: Use of an effective contraceptive method during the study period (see Annex 5 for details)
• Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted
• Able to adhere to the study visit schedule and other protocol requirements
• Patient registered to the French Social Security

Exclusion criteria

• Segmental or mixed vitiligo
• Other than vitiligo, history of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.
• Any condition which would place the subject at unacceptable risk if he/she were to participate in the study.
• Any condition that confounds the ability to interpret data from the study.
• Pregnant or breast feeding, pregnancy urinary tests will be performed (see Annex 5 for details about pregnancy testing and contraception)
• History of allergy to any component of apremilast
• History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease)
• Active substance abuse or a history of substance abuse within 6 months prior to Screening
• Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed at least 4 weeks prior to Screening.
• Malignancy or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence)
• Evidence of skin conditions that would interfere with clinical assessments
• Topical therapy within 2 weeks of randomization
• Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources
• Prior treatment with apremilast
• Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA)
• Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives,
• Patients assessed to be uncooperative
• Participants in other clinical studies
• Vulnerable people: pregnant or breast-feeding women (an urinary pregnancy test will be realized in every visit), minors, adults under guardianship or guardianship, deprived of freedom
• Patient with a rare hereditary disease such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome
• Patient with severe renal insufficiency